CLN6 disease

CLN6 disease (Orphanet code 228363) is a rare inherited neurodegenerative disorder belonging to the group of neuronal ceroid lipofuscinoses (NCLs), sometimes collectively referred to as Batten disease. It is caused by mutations in the CLN6 gene, which encodes a transmembrane protein of the endoplasmic reticulum involved in lysosomal function. The disease leads to abnormal accumulation of ceroid lipofuscin, a lipopigment, within cells of the brain and other tissues, resulting in progressive neuronal damage. CLN6 disease presents in two main clinical forms. The late-infantile variant (also known as CLN6 late-infantile NCL or variant late-infantile neuronal ceroid lipofuscinosis) typically manifests between ages 18 months and 8 years with seizures, progressive loss of motor and cognitive skills, visual impairment progressing to blindness, speech deterioration, ataxia, and myoclonus. The adult-onset form, sometimes called Kufs disease type A, presents later in life with progressive myoclonus epilepsy, cognitive decline, and motor dysfunction, but often without the visual loss seen in the childhood form. Both forms primarily affect the central nervous system, with the brain being the most severely impacted organ. There is currently no cure for CLN6 disease. Treatment is supportive and symptomatic, focusing on seizure management with antiepileptic medications, physical and occupational therapy to maintain function, nutritional support, and palliative care as the disease progresses. Gene therapy approaches are under active investigation in clinical trials, offering potential hope for future disease-modifying treatment. The prognosis varies by form, with the late-infantile variant typically leading to severe disability and premature death in childhood or adolescence, while the adult-onset form progresses more slowly.

Common questions about CLN6 disease